Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

GenVec/Parke-Davis BioByPass set to enter clinicals in early 1998; companies sign $100 mil. R&D agreement.

  • News

Executive Summary

GENVEC/PARKE-DAVIS BIOBYPASS TO BEGIN CLINICALS IN FIRST QUARTER 1998 in the initial indication of coronary artery disease. Patients in the trial will receive a one-time injection to the left ventricle of the gene therapy product, which delivers the vascular endothelial growth factor gene via an adenovirus vector. GenVec licenses the VEGF gene from Scios. A second study in peripheral vascular disease with BioByPass will follow soon after the first study.

Table

View full table

Tags:
Latest Headlines

AI Used In Drug R&D Likely Exempt From Tough EU AI Rules, Says EFPIA

EU Parliament OKs New Rules On Use Of Patient Data In Research

Danes Advise Pharma Firms To Test Their Anti-Tamper Devices

Joint Clinical Assessments: EU Guidance On Evidence May Be Flexible For ATMPs And Single Arm Trials

See All
UsernamePublicRestriction

Register

PS030858

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By